12. Segments

3 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

12. Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

	Three Months Ended June 30,
	2015			2014
Revenues:
Aethlon	$	192,508		$	51,296
ESI		–			–
Total Revenues	$	192,508		$	51,296
Operating Losses:
Aethlon	$	(921,859	)	$	(930,252	)
ESI		(168,112	)		(241,756	)
Total Operating Loss	$	(1,089,971	)	$	(1,172,008	)
Net Losses:
Aethlon	$	(1,048,547	)	$	(3,462,536	)
ESI		(168,112	)		(241,756	)
Net Loss Before Non-Controlling Interests	$	(1,216,659	)	$	(3,704,292	)
Cash:
Aethlon	$	5,647,132		$	45,704
ESI		2,446			761,626
Total Cash	$	5,649,578		$	807,330
Total Assets:
Aethlon	$	5,912,926		$	294,662
ESI		61,110			849,786
Total Assets	$	5,974,036		$	1,144,448
Capital Expenditures:
Aethlon	$	–		$	–
ESI		–			–
Capital Expenditures	$	–		$	–
Depreciation and Amortization:
Aethlon	$	4,443		$	4,442
ESI		4,895			4,896
Total Depreciation and Amortization	$	9,338		$	9,338
Interest Expense:
Aethlon	$	(126,688	)	$	(78,654	)
ESI		–			–
Total Interest Expense	$	(126,688	)	$	(78,654	)